Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Haemophilia prophylactic licensed

  • Comment

A prophylactic agent has been granted a license for haemophilia A patients with inhibitors.

Factor VIII Inhibitor Bypassing Activity (FEIBA) reduces a patient’s risk of spontaneous bleeds, minimising long-term complications, according to manufacturer Baxter. It is the first bypassing agent to be granted a prophylaxis indication for this group of patients.

Kate Khair, nurse consultant in haemophilia at Great Ormond Street Hospital in London, said: ‘Treating patients with inhibitors with FEIBA prophylaxis has a profound effect on the everyday life of a patient.’

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.